George A. Joulwan - 26 May 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: Director
Issuer ticker: EBS
Reported as of: 26 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 May 2022, 16:20:57 UTC
Prior SEC filing: 24 May 2021
Source filing: View source filing
Reporting owner signature: /s/ S. Scott Lieberman, Attorney-in-fact

Key filing fact

George A. Joulwan filed Form 4 for Emergent BioSolutions Inc. (EBS) on 31 May 2022.

Key facts

This page summarizes George A. Joulwan's Form 4 filing for Emergent BioSolutions Inc. (EBS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 May 2022, 16:20.

Change

Previous filing in this sequence was filed on 24 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +8,446
Change %: +27%
Price: $0.000000
Shares after: 40,244
Date: 26 May 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.

Footnote F2

These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company.